APO Research
Talk to an analyst

APO RESEARCH · REPORT

End-Stage Renal Disease (ESRD) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global End-Stage Renal Disease (ESRD) Drugs Market Outlook and Growth Opportunities 2026

19 December 2025197 pages

Choose your research edition.

Industry ResearchEnd-Stage Renal Disease (ESRD) Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal End-Stage Renal Disease (ESRD) Drugs Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal End-Stage Renal Disease (ESRD) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal End-Stage Renal Disease (ESRD) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal End-Stage Renal Disease (ESRD) Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global End-Stage Renal Disease (ESRD) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for End-Stage Renal Disease (ESRD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for End-Stage Renal Disease (ESRD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for End-Stage Renal Disease (ESRD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the End-Stage Renal Disease (ESRD) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the End-Stage Renal Disease (ESRD) Drugs market include Novartis AG, Merck & Co Inc, VESSL Therapeutics Ltd, Prolong Pharmaceuticals LLC and CTI BioPharma Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global End-Stage Renal Disease (ESRD) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of End-Stage Renal Disease (ESRD) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents End-Stage Renal Disease (ESRD) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the End-Stage Renal Disease (ESRD) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

End-Stage Renal Disease (ESRD) Drugs Segment by Company

Novartis AG

Merck & Co Inc

VESSL Therapeutics Ltd

Prolong Pharmaceuticals LLC

CTI BioPharma Corp

End-Stage Renal Disease (ESRD) Drugs Segment by Type

Sanguinate

Tesidolumab

Calcium Succinate

Mk-3866

Pacritinib

Others

End-Stage Renal Disease (ESRD) Drugs Segment by Application

ICU

Hospital

Clinic

Others

End-Stage Renal Disease (ESRD) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global End-Stage Renal Disease (ESRD) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions End-Stage Renal Disease (ESRD) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify End-Stage Renal Disease (ESRD) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze End-Stage Renal Disease (ESRD) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global End-Stage Renal Disease (ESRD) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of End-Stage Renal Disease (ESRD) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of End-Stage Renal Disease (ESRD) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the End-Stage Renal Disease (ESRD) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global End-Stage Renal Disease (ESRD) Drugs industry.

Chapter 3: Detailed analysis of End-Stage Renal Disease (ESRD) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of End-Stage Renal Disease (ESRD) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of End-Stage Renal Disease (ESRD) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. End-Stage Renal Disease (ESRD) Drugs Industry Trends Table 2. End-Stage Renal Disease (ESRD) Drugs Industry Drivers Table 3. End-Stage Renal Disease (ESRD) Drugs Industry Opportunities and Challenges Table 4. End-Stage Renal Disease (ESRD) Drugs Industry Restraints Table 5. Global End-Stage Renal Disease (ESRD) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global End-Stage Renal Disease (ESRD) Drugs Revenue Share by Company (2021-2026) Table 7. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Share by Company (2021-2026) Table 9. Global End-Stage Renal Disease (ESRD) Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global End-Stage Renal Disease (ESRD) Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global End-Stage Renal Disease (ESRD) Drugs Key Company Manufacturing Base & Headquarters Table 12. Global End-Stage Renal Disease (ESRD) Drugs Company, Product Type & Application Table 13. Global End-Stage Renal Disease (ESRD) Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global End-Stage Renal Disease (ESRD) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Sanguinate Table 18. Significant Companies of Tesidolumab Table 19. Significant Companies of Calcium Succinate Table 20. Significant Companies of Mk-3866 Table 21. Significant Companies of Pacritinib Table 22. Significant Companies of Others Table 23. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Type (2021-2026) & (K Units) Table 25. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Type (2027-2032) & (K Units) Table 26. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Share by Type (2021-2026) Table 27. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Share by Type (2027-2032) Table 28. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type (2021-2026) Table 32. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type (2027-2032) Table 33. Significant Companies of ICU Table 34. Significant Companies of Hospital Table 35. Significant Companies of Clinic Table 36. Significant Companies of Others Table 37. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Application (2021-2026) & (K Units) Table 39. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Application (2027-2032) & (K Units) Table 40. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Share by Application (2021-2026) Table 41. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Share by Application (2027-2032) Table 42. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application (2021-2026) Table 46. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application (2027-2032) Table 47. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2021-2026) & (K Units) Table 49. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2021-2026) Table 50. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2027-2032) & (K Units) Table 51. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region (2027-2032) Table 52. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Region (2021-2026) Table 55. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Region (2027-2032) Table 57. Global End-Stage Renal Disease (ESRD) Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global End-Stage Renal Disease (ESRD) Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global End-Stage Renal Disease (ESRD) Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2026) & (K Units) Table 62. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2021-2026) Table 63. Global End-Stage Renal Disease (ESRD) Drugs Sales by Country (2027-2032) & (K Units) Table 64. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Country (2027-2032) Table 65. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Market Share by Country (2021-2026) Table 67. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Market Share by Country (2027-2032) Table 69. Novartis AG Company Information Table 70. Novartis AG Business Overview Table 71. Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novartis AG End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 73. Novartis AG Recent Development Table 74. Merck & Co Inc Company Information Table 75. Merck & Co Inc Business Overview Table 76. Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 78. Merck & Co Inc Recent Development Table 79. VESSL Therapeutics Ltd Company Information Table 80. VESSL Therapeutics Ltd Business Overview Table 81. VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 83. VESSL Therapeutics Ltd Recent Development Table 84. Prolong Pharmaceuticals LLC Company Information Table 85. Prolong Pharmaceuticals LLC Business Overview Table 86. Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 88. Prolong Pharmaceuticals LLC Recent Development Table 89. CTI BioPharma Corp Company Information Table 90. CTI BioPharma Corp Business Overview Table 91. CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product Portfolio Table 93. CTI BioPharma Corp Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. End-Stage Renal Disease (ESRD) Drugs Distributors List Table 97. End-Stage Renal Disease (ESRD) Drugs Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. End-Stage Renal Disease (ESRD) Drugs Product Image Figure 2. Global End-Stage Renal Disease (ESRD) Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global End-Stage Renal Disease (ESRD) Drugs Sales (2021-2032) & (K Units) Figure 5. Global End-Stage Renal Disease (ESRD) Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global End-Stage Renal Disease (ESRD) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Sanguinate Image Figure 10. Tesidolumab Image Figure 11. Calcium Succinate Image Figure 12. Mk-3866 Image Figure 13. Pacritinib Image Figure 14. Others Image Figure 15. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Share by Type (2021-2032) Figure 18. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type (2021-2032) Figure 21. ICU Image Figure 22. Hospital Image Figure 23. Clinic Image Figure 24. Others Image Figure 25. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Share by Application (2021-2032) Figure 28. Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application (2021-2032) Figure 31. Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. North America End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Europe End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. South America End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. End-Stage Renal Disease (ESRD) Drugs Value Chain Figure 130. Manufacturing Cost Structure Figure 131. End-Stage Renal Disease (ESRD) Drugs Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Sanguinate
  • Tesidolumab
  • Calcium Succinate
  • Mk-3866
  • Pacritinib
  • Others
Applications
  • ICU
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co Inc
  • VESSL Therapeutics Ltd
  • Prolong Pharmaceuticals LLC
  • CTI BioPharma Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032)
  4. 1.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 End-Stage Renal Disease (ESRD) Drugs Market Dynamics
  1. 2.1 End-Stage Renal Disease (ESRD) Drugs Industry Trends
  2. 2.2 End-Stage Renal Disease (ESRD) Drugs Industry Drivers
  3. 2.3 End-Stage Renal Disease (ESRD) Drugs Industry Opportunities and Challenges
  4. 2.4 End-Stage Renal Disease (ESRD) Drugs Industry Restraints
3 End-Stage Renal Disease (ESRD) Drugs Market by Company
  1. 3.1 Global End-Stage Renal Disease (ESRD) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global End-Stage Renal Disease (ESRD) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global End-Stage Renal Disease (ESRD) Drugs Average Price by Company (2021-2026)
  5. 3.5 Global End-Stage Renal Disease (ESRD) Drugs Company Ranking (2024-2026)
  6. 3.6 Global End-Stage Renal Disease (ESRD) Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global End-Stage Renal Disease (ESRD) Drugs Company Product Type and Application
  8. 3.8 Global End-Stage Renal Disease (ESRD) Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global End-Stage Renal Disease (ESRD) Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 End-Stage Renal Disease (ESRD) Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 End-Stage Renal Disease (ESRD) Drugs Market by Type
  1. 4.1 End-Stage Renal Disease (ESRD) Drugs Type Introduction
  2. 4.1.1 Sanguinate
  3. 4.1.2 Tesidolumab
  4. 4.1.3 Calcium Succinate
  5. 4.1.4 Mk-3866
  6. 4.1.5 Pacritinib
  7. 4.1.6 Others
  8. 4.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Type
  9. 4.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Type (2021-2032)
  11. 4.2.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Share by Type (2021-2032)
  12. 4.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Type
  13. 4.3.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Type (2021-2032)
  15. 4.3.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type (2021-2032)
5 End-Stage Renal Disease (ESRD) Drugs Market by Application
  1. 5.1 End-Stage Renal Disease (ESRD) Drugs Application Introduction
  2. 5.1.1 ICU
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Others
  6. 5.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Application
  7. 5.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Application
  11. 5.3.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application (2021-2032)
6 End-Stage Renal Disease (ESRD) Drugs Regional Sales and Value Analysis
  1. 6.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Region (2027-2032)
  5. 6.3 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global End-Stage Renal Disease (ESRD) Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032)
  12. 6.6.2 North America End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032)
  21. 6.9.2 South America End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Country, 2025 VS 2032
7 End-Stage Renal Disease (ESRD) Drugs Country-level Sales and Value Analysis
  1. 7.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global End-Stage Renal Disease (ESRD) Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global End-Stage Renal Disease (ESRD) Drugs Sales by Country (2027-2032)
  6. 7.4 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global End-Stage Renal Disease (ESRD) Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt End-Stage Renal Disease (ESRD) Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt End-Stage Renal Disease (ESRD) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck & Co Inc
  8. 8.2.1 Merck & Co Inc Company Information
  9. 8.2.2 Merck & Co Inc Business Overview
  10. 8.2.3 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  12. 8.2.5 Merck & Co Inc Recent Developments
  13. 8.3 VESSL Therapeutics Ltd
  14. 8.3.1 VESSL Therapeutics Ltd Company Information
  15. 8.3.2 VESSL Therapeutics Ltd Business Overview
  16. 8.3.3 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  18. 8.3.5 VESSL Therapeutics Ltd Recent Developments
  19. 8.4 Prolong Pharmaceuticals LLC
  20. 8.4.1 Prolong Pharmaceuticals LLC Company Information
  21. 8.4.2 Prolong Pharmaceuticals LLC Business Overview
  22. 8.4.3 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  24. 8.4.5 Prolong Pharmaceuticals LLC Recent Developments
  25. 8.5 CTI BioPharma Corp
  26. 8.5.1 CTI BioPharma Corp Company Information
  27. 8.5.2 CTI BioPharma Corp Business Overview
  28. 8.5.3 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Product Portfolio
  30. 8.5.5 CTI BioPharma Corp Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 End-Stage Renal Disease (ESRD) Drugs Value Chain Analysis
  2. 9.1.1 End-Stage Renal Disease (ESRD) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 End-Stage Renal Disease (ESRD) Drugs Sales Mode & Process
  6. 9.2 End-Stage Renal Disease (ESRD) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 End-Stage Renal Disease (ESRD) Drugs Distributors
  9. 9.2.3 End-Stage Renal Disease (ESRD) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst